← All trials
NCT04488705
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2020
- Primary completion
- Dec 30, 2020
- Completion date
- Dec 30, 2020
- First posted
- Jul 28, 2020
- Last posted
- Aug 17, 2020
- Enrollment
- 88
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Enterprise Therapeutics LtdLead sponsor
- Enterprise Therapeutics LtdStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.